MCID: OVR049
MIFTS: 52

Ovarian Disease

Categories: Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Disease

MalaCards integrated aliases for Ovarian Disease:

Name: Ovarian Disease 12 15 17
Ovarian Dysfunction 12 54 15 17 32
Ovarian Diseases 54 43 71
Disorder of Endocrine Ovary 71
Ovarian Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:1100 DOID:1414
ICD9CM 34 256.3
MeSH 43 D010049
NCIt 49 C26841
SNOMED-CT 67 5552004
ICD10 32 E28 E28.3 E28.9
UMLS 71 C0029697 C0029928 C0154208

Summaries for Ovarian Disease

MedlinePlus : 42 The ovaries are part of the female reproductive system. Women have two ovaries, one on each side of the uterus. Each ovary is about the size and shape of an almond. The ovaries produce and store a woman's eggs. During ovulation, an ovary releases an egg. If that egg is fertilized by a sperm, a pregnancy can occur. Ovaries also make the female hormones estrogen and progesterone. When a woman goes through menopause, her ovaries stop making those hormones and releasing eggs. Problems with the ovaries include Ovarian cancer Ovarian cysts and polycystic ovary syndrome Primary ovarian insufficiency Ovarian torsion, a twisting of the ovary

MalaCards based summary : Ovarian Disease, also known as ovarian dysfunction, is related to estrogen excess and polycystic ovary syndrome, and has symptoms including pelvic pain and mittelschmerz. An important gene associated with Ovarian Disease is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are mTOR signaling pathway (KEGG) and Immune response IFN alpha/beta signaling pathway. The drugs Sodium citrate and Metformin have been mentioned in the context of this disorder. Affiliated tissues include ovary, pituitary and breast, and related phenotypes are endocrine/exocrine gland and integument

Disease Ontology : 12 An ovarian disease that is characterized by irregular or absent ovulation.

Wikipedia : 74 Ovarian diseases are conditions that happen to young women and can affect their reproductive system and... more...

Related Diseases for Ovarian Disease

Diseases in the Ovarian Disease family:

Ovarian Insufficiency, Familial

Diseases related to Ovarian Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 346)
# Related Disease Score Top Affiliating Genes
1 estrogen excess 33.9 SHBG PRL GNRH1 FSHR FOXL2 CYP19A1
2 polycystic ovary syndrome 33.6 SHBG PRL INS IGFBP1 IGF1 GNRH1
3 premature menopause 33.4 GNRH1 GDF9 FSHR FOXL2 FMR1 CYP19A1
4 galactosemia i 33.3 GDF9 FOXL2 AMH
5 ovarian cyst 33.3 PRL GNRH1 FOXL2 CYP19A1 CGA AMH
6 anovulation 33.3 SHBG PRL INS IGFBP1 IGF1 GNRH1
7 ovarian hyperstimulation syndrome 33.3 SHBG INS GNRH1 FSHR CYP19A1 CGA
8 premature ovarian failure 1 33.1 ZP3 SHBG PRL INS IGF1 GNRH1
9 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 32.6 INS IGF1
10 hyperinsulinism 31.7 SHBG INS IGFBP1 IGF1R IGF1 GNRH1
11 hyperandrogenism 31.7 SHBG PRL INS IGFBP1 IGF1 GNRH1
12 infertility 31.6 ZP3 SHBG PRL GNRH1 GDF9 FSHR
13 amenorrhea 31.5 SHBG PRL INS IGF1 GNRH1 GDF9
14 hyperprolactinemia 31.5 SHBG PRL INS IGF1 GNRH1 CGA
15 acanthosis nigricans 31.3 SHBG PRL INS IGF1R IGF1
16 insulin-like growth factor i 31.3 SHBG PRL INS IGFBP1 IGF1R IGF1
17 endometriosis 31.1 MIR199A1 MIR141 IGFBP1 GNRH1 FSHR CYP19A1
18 lipoid congenital adrenal hyperplasia 31.1 SHBG PRL INS GNRH1 CYP19A1 AMH
19 diabetes mellitus 31.0 TNF SHBG PRL INS IGFBP1 IGF1R
20 hypogonadotropic hypogonadism 31.0 SHBG PRL INS GNRH1 CYP19A1 AMH
21 mccune-albright syndrome 31.0 PRL IGF1 CYP19A1 AMH
22 pituitary gland disease 30.9 PRL INS IGF1 GNRH1 CGA
23 hypogonadism 30.9 SHBG PRL INS IGF1 GNRH1 CYP19A1
24 gestational diabetes 30.9 TNF SHBG INS IGFBP1 IGF1
25 luteoma 30.9 SHBG GNRH1 FSHR FOXL2 CYP19A1 CGA
26 endometriosis of ovary 30.8 MIR141 GNRH1 CYP19A1 AMH
27 gonadal dysgenesis 30.8 SHBG GDF9 FSHR FOXL2 AMH
28 galactorrhea 30.8 PRL IGF1
29 endometrial cancer 30.8 SHBG MIR199A1 MIR141 INS IGFBP1 IGF1R
30 hyperthyroidism 30.8 TNF SHBG PRL INS IGF1 CGA
31 diabetes mellitus, noninsulin-dependent 30.8 TNF SHBG MIR483 MIR29A MIR199A1 INS
32 prader-willi syndrome 30.8 TNF PRL INS IGFBP1 IGF1 GNRH1
33 turner syndrome 30.8 SHBG PRL INS IGFBP1 IGF1 FMR1
34 osteoporosis 30.8 TNF SHBG PRL INS IGFBP1 IGF1R
35 vaginal discharge 30.8 TNF GNRH1 CYP19A1
36 myoma 30.7 GNRH1 CYP19A1 AMH
37 body mass index quantitative trait locus 11 30.7 TNF SHBG PRL MIR483 MIR29A MIR199A1
38 ovarian cancer 30.7 TNF MIR483 MIR29A MIR199A1 MIR141 INS
39 acromegaly 30.7 SHBG PRL INS IGFBP1 IGF1 GNRH1
40 empty sella syndrome 30.7 PRL INS IGF1 GNRH1
41 gynecomastia 30.7 SHBG PRL GNRH1 CYP19A1 CGA
42 anorexia nervosa 30.7 SHBG PRL INS IGFBP1 IGF1
43 thyroiditis 30.7 TNF PRL INS
44 hypothyroidism 30.6 TNF SHBG PRL INS IGF1 GNRH1
45 disorders of sexual development 30.6 SHBG PRL MIR483 INS IGF1 GNRH1
46 corpus luteum cyst 30.6 GNRH1 FOXL2
47 chronic salpingo-oophoritis 30.6 PRL AMH
48 adenomyosis 30.6 PRL GNRH1 CYP19A1
49 pseudohermaphroditism 30.5 FSHR CYP19A1 AMH
50 bipolar disorder 30.1 TNF SHBG PRL IGFBP1 IGF1

Graphical network of the top 20 diseases related to Ovarian Disease:



Diseases related to Ovarian Disease

Symptoms & Phenotypes for Ovarian Disease

UMLS symptoms related to Ovarian Disease:


pelvic pain, mittelschmerz

MGI Mouse Phenotypes related to Ovarian Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.17 AMH CGA CYP19A1 FMR1 FOXL2 FSHR
2 integument MP:0010771 9.91 CYP19A1 FMR1 FSHR GNRH1 IGF1 IGF1R
3 liver/biliary system MP:0005370 9.7 CYP19A1 GNRH1 IGF1R IGFBP1 INS PRL
4 neoplasm MP:0002006 9.5 AMH FSHR GNRH1 IGF1 IGF1R PRL
5 reproductive system MP:0005389 9.47 AMH CGA CYP19A1 FMR1 FOXL2 FSHR

Drugs & Therapeutics for Ovarian Disease

Drugs for Ovarian Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Metformin Approved Phase 4 657-24-9 14219 4091
3
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
4
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
5
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
6
Enclomiphene Investigational Phase 4 15690-57-0
7 Citrate Phase 4
8 Chelating Agents Phase 4
9 Clomiphene Phase 4
10 Anticoagulants Phase 4
11 Calcium, Dietary Phase 4
12 Zuclomiphene Phase 4
13 Insulin, Globin Zinc Phase 4
14 insulin Phase 4
15 Hypoglycemic Agents Phase 4
16 Antineoplastic Agents, Hormonal Phase 4
17
Calcium Nutraceutical Phase 4 7440-70-2 271
18
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
19
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
20
Goserelin Approved Phase 3 65807-02-5 5311128 47725
21
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
22
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
23
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
24
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
25
Bevacizumab Approved, Investigational Phase 3 216974-75-3
26
Exenatide Approved, Investigational Phase 3 141758-74-9 15991534
27
Phentermine Approved, Illicit Phase 3 122-09-8 4771
28
Glucagon Approved Phase 3 16941-32-5
29
Topiramate Approved Phase 3 97240-79-4 5284627
30 Antirheumatic Agents Phase 3
31 Alkylating Agents Phase 3
32 Antimetabolites Phase 3
33 Hormone Antagonists Phase 3
34 Hormones Phase 3
35 Angiogenesis Inhibitors Phase 3
36 Antineoplastic Agents, Immunological Phase 3
37 Albumin-Bound Paclitaxel Phase 3
38 Tubulin Modulators Phase 3
39 Antimitotic Agents Phase 3
40 Gastrointestinal Agents Phase 3
41 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 3
42 Central Nervous System Stimulants Phase 3
43 Anti-Obesity Agents Phase 3
44 Adrenergic Agents Phase 3
45 Sodium-Glucose Transporter 2 Inhibitors Phase 3
46 Glucagon-Like Peptide 1 Phase 3
47 Appetite Depressants Phase 3
48 Sympathomimetics Phase 3
49 Anticonvulsants Phase 3
50 Neurotransmitter Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
2 Combined Influence of Puberty and Obesity on Insulin Resistance in Adolescents Completed NCT01775813 Phase 4 Metformin
3 CLASSICAL ANTAGONIST PROTOCOL IN COMPARISON WITH AGONIST STOP PROTOCOL IN Polycystic Ovary Symdrome WOMEN UNDERGOING Intra-cytoplasmic Injection TRIAL: a Randomized Controlled Trial Recruiting NCT04094467 Phase 4 Cetrorelix;Leuprolide Acetate
4 Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
5 Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy Versus Conventional Preoperative Radiochemotherapy for Locally Advanced Rectal Cancer With MRI Negative Circumferential Margin Recruiting NCT02121405 Phase 3 Capecitabine;Oxaliplatin
6 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin
7 Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women Active, not recruiting NCT02635386 Phase 3 Exenatide once weekly (EQW );Dapagliflozin (DAPA);EQW plus DAPA;Dapagliflozin plus Glucophage (MET ER);Phentermine /Topiramate (PHEN/ TRP) ER
8 A Prospective, Controlled, Randomized, Multi-Center, Exploratory Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil Unknown status NCT00544310 Phase 1, Phase 2
9 Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma Completed NCT01460979 Phase 2 Temsirolimus
10 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
11 Prospective Randomized Controlled Trial of Antral Follicle Priming Prior to IVF-ICSI in Previously Diagnosed Low Responders. Completed NCT01310647 Phase 2 Testosterone;Estradiol;CombEq
12 Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer Completed NCT01610869 Phase 2 BIBF 1120
13 Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer Completed NCT00050414 Phase 2 Trabectedin;Dexamethasone
14 Phase II Study of Weekly Paclitaxel/Carboplatin in Combination With Prophylactic G-CSF in the Treatment of Gynaecological Cancers Completed NCT01523678 Phase 2 Filgrastim;Paclitaxel;Carboplatin
15 Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia Completed NCT03715413 Phase 2 Tamoxifen
16 Multisite Double-Blind Randomized Controlled Study of Estradiol Plus Antipsychotic Versus Placebo Plus Antipsychotic in the Treatment of Psychotic Symptoms in Women With Schizophrenia Completed NCT00357006 Phase 2 Estradiol;Estradiol
17 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction Recruiting NCT03229408 Phase 2 Salsalate
18 A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer Recruiting NCT03983226 Phase 2 carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...;Niraparib
19 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
20 A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in Active, not recruiting NCT02915523 Phase 1, Phase 2 entinostat;avelumab;Placebo
21 Phase II Study of Four Dose Levels of Intraperitoneal NanoPac® Plus IV Carboplatin and Paclitaxel in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery Active, not recruiting NCT03029585 Phase 2 NanoPac® 100 mg/m2;NanoPac® 200 mg/m2;NanoPac® 300 mg/m2;NanoPac® 400 mg/m2;Standard of Care Intravenous Chemotherapy
22 A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers Active, not recruiting NCT03073525 Phase 2 Atezolizumab
23 A Phase II Trial of GnRH Agonist for the Preservation of Ovarian Function After Hematopoietic Cell Transplantation (HCT) Terminated NCT01343368 Phase 2 Leuprolide
24 A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Terminated NCT03146663 Phase 2 NUC-1031 500 mg;NUC-1031 750mg
25 Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial Unknown status NCT02024984 Phase 1 Clomiphene Citrate
26 A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-8M4 Given as Monotherapy in Subjects With Advanced Ovarian Cancer Completed NCT00816764 Phase 1
27 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
28 89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g Completed NCT01832116 Phase 1 89Zr-MMOT0530A
29 Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Stem Cell (MSC)-Like Cells Transplantation in Women With Primary Ovarian Insufficiency (POI) Recruiting NCT03877471 Phase 1
30 A Phase 1b, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Two Different Chemotherapy Regimens in Women With Platinum Resistant or Platinum Sensitive Ovarian Cancer Terminated NCT01016054 Phase 1 Pegylated liposomal doxorubicin (PLD);gemcitabine;carboplatin
31 The Role of Inactive Follicle Stimulating Hormone in Ovarian Dysfunction in Galactosemia Unknown status NCT00619333 follitropin and lutropin
32 Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT02402413
33 Mediterranean Diet Versus Hypocaloric Diet: What is the Best Choice for the Treatment of Polycystic Ovary Syndrome (PCOS)? Unknown status NCT02397174
34 Mediterranean Diet: A New Nutritional Approach for the Treatment of Normal Weight Women With Polycystic Ovary Syndrome (PCOS)? Unknown status NCT02396264
35 Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome - a Study on Multigenerational Families Unknown status NCT00665171
36 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone Unknown status NCT00928044
37 The Effect of Diet on the Microbiome of Women With Polycystic Ovary Syndrome Unknown status NCT02078505
38 A Multiple Patient Expanded Access Program for Olaparib Tablets for the Maintenance Treatment Following Response (Complete Response or Partial Response) to Platinum-based Chemotherapy in Patients With Platinum-sensitive Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Approved for marketing NCT03079687 Olaparib tablets
39 Pathogenesis of Functional Hypothalamic Amenorrhea Completed NCT01674426
40 Comparison of 2 Techniques of Invasive Mini Surgery: Coelioscopy Mini-trocar and Monotrocar in the Adnexa no Carcinologic Surgery : Forward-looking Observational Study. Completed NCT02885779
41 Timing of Development in Embryos Derived From Women With Polycystic Ovairan Syndrome and Controls Completed NCT01953146
42 The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy Completed NCT03593681
43 Feasability of Transgastric Adnexectomy Completed NCT01566955
44 Evaluation of Ovarian Reserve Using Anti-müllerian Hormone and Antral Follicle Count in Ankylosing Spondylitis: Preliminary Study Completed NCT04209881
45 To Study the Efficacy and Safety of Furocyst in Poly Cystic Ovary Syndrome Patients (PCOS) Completed NCT02703064
46 Assessment of Endometrial Thickness & Subendometrial Perfusion by 3D Power Doppler in Women With Unexplained Infertility and PCOS. Completed NCT03397693
47 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
48 Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project Completed NCT00776958
49 Hospital Based Pilot Study: Association of Kisspeptin Levels With Insulin Secretion in Diabetes Mellitus Completed NCT01956851
50 Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives Recruiting NCT01411644

Search NIH Clinical Center for Ovarian Disease

Cochrane evidence based reviews: ovarian diseases

Genetic Tests for Ovarian Disease

Anatomical Context for Ovarian Disease

MalaCards organs/tissues related to Ovarian Disease:

40
Ovary, Pituitary, Breast, Uterus, Testes, T Cells, Thyroid

Publications for Ovarian Disease

Articles related to Ovarian Disease:

(show top 50) (show all 1968)
# Title Authors PMID Year
1
EVALUATION OF THE RISK FACTORS OF CERVICAL INSUFFICIENCY IN WOMEN WITH INFERTILITY ASSOCIATED WITH ANOVULATION. 42
32141843 2020
2
Association of obesity and anovulatory infertility. 42
32159605 2020
3
Serum progesterone concentrations on the day of oocyte retrieval above 9.23 ng/ml may predict ovarian hyperstimulation syndrome risk in in vitro fertilized patients. 42
32009632 2019
4
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 61 54
19342032 2010
5
FOXL2 copy number changes in the molecular pathogenesis of BPES: unique cohort of 17 deletions. 61 54
20232352 2010
6
Towards a functional classification of pathogenic FOXL2 mutations using transactivation reporter systems. 61 54
19515849 2009
7
Premature ovarian failure and fragile X female premutation carriers: no evidence for a skewed X-chromosome inactivation pattern. 54 61
19373114 2009
8
Characterization of functionally typical and atypical types of polycystic ovary syndrome. 54 61
19240152 2009
9
FOXL2 mutations and genomic rearrangements in BPES. 54 61
18726931 2009
10
A distribution of two SNPs in exon 10 of the FSHR gene among the women with a diminished ovarian reserve in Ukraine. 54 61
19031050 2009
11
Ovarian dysfunction and FMR1 alleles in a large Italian family with POF and FRAXA disorders: case report. 54 61
17428316 2007
12
A novel polyalanine expansion in FOXL2: the first evidence for a recessive form of the blepharophimosis syndrome (BPES) associated with ovarian dysfunction. 54 61
17089161 2007
13
The empty follicle syndrome. 61 54
17243533 2006
14
Gonadotropin-releasing hormone (GnRH) and its natural analogues: a review. 61 54
16650469 2006
15
Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. 61 54
16361284 2006
16
FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. 54 61
16758348 2006
17
A new heterozygous mutation of the FOXL2 gene is associated with a large ovarian cyst and ovarian dysfunction in an adolescent girl with blepharophimosis/ptosis/epicanthus inversus syndrome. 61 54
16131596 2005
18
Premature ovarian failure and forkhead transcription factor FOXL2: blepharophimosis-ptosis-epicanthus inversus syndrome and ovarian dysfunction. 54 61
16208278 2005
19
Recurrent severe hyperandrogenism during pregnancy: a case report. 54 61
15790717 2005
20
Molecular cloning of porcine growth differentiation factor 9 (GDF-9) cDNA and its role in early folliculogenesis: direct ovarian injection of GDF-9 gene fragments promotes early folliculogenesis. 61 54
15509699 2004
21
Pregnancy and renal transplantation. 61 54
15013320 2004
22
Electro-acupuncture reverses nerve growth factor abundance in experimental polycystic ovaries in the rat. 54 61
14671415 2004
23
The effect of herbal medicine on nerve growth factor in estradiol valerate-induced polycystic ovaries in rats. 54 61
14992541 2003
24
Molecular approach to common causes of female infertility. 54 61
12475548 2002
25
Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. 61 54
11927624 2002
26
The female and the fragile X reviewed. 54 61
11480913 2001
27
Long-term GnRH analogue treatment is equivalent to laparoscopic laser diathermy in polycystic ovarian syndrome patients with severe ovarian dysfunction. 54 61
11098021 2000
28
Induction of ovulation after gnRH antagonists. 54 61
10972519 2000
29
Gonadotropins and cytokines affect luteal function through control of apoptosis in human luteinized granulosa cells. 61 54
10770207 2000
30
Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. 61 54
10690875 2000
31
Design and evaluation of a ZP3 peptide vaccine in a homologous primate model. 61 54
10321806 1999
32
Treatment of cystic ovarian disease in dairy cows with gonadotrophin-releasing hormone: a field study. 61 54
9990705 1999
33
OVCA (CA125) second generation: technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease. 61 54
9226027 1997
34
GnRH analog administration in patients with polycystic ovarian disease. 54 61
7589755 1995
35
Regulation of galactose-1-phosphate uridyltransferase gene expression. 61 54
7671960 1995
36
Randomised controlled trial of the use of human chorionic gonadotrophin in recurrent miscarriage associated with polycystic ovaries. 61 54
7947503 1994
37
Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. 54 61
8157196 1994
38
Endocrine features in eutestosteronemic women with polycystic ovaries. 54 61
8150364 1994
39
The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. 61 54
8150903 1993
40
Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease. 54 61
8291452 1993
41
Ovarian electrocauterization causes LH-regulated but not insulin-regulated endocrine changes. 61 54
7690311 1993
42
Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease. 61 54
7685718 1993
43
Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. 54 61
1399109 1992
44
Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. 54 61
1633889 1992
45
Androstenedione as a predictor of ovarian hyperstimulation syndrome. 54 61
1430128 1992
46
Pharmacologic manipulation of fertility. 61 54
1555118 1992
47
Clinical applications of GnRH and its analogues. 61 54
18407075 1992
48
Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. 61 54
1708731 1991
49
Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease. 61 54
1898892 1991
50
A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction. 61 54
2245840 1990

Variations for Ovarian Disease

Expression for Ovarian Disease

Search GEO for disease gene expression data for Ovarian Disease.

Pathways for Ovarian Disease

GO Terms for Ovarian Disease

Cellular components related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ZP3 TNF SHBG PRL INS IGFBP1
2 extracellular space GO:0005615 9.44 ZP3 TNF PRL MIR29A MIR199A1 MIR141
3 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 9.16 IGF1R IGF1

Biological processes related to Ovarian Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 PRL INS IGFBP1 IGF1R IGF1 GNRH1
2 positive regulation of gene expression GO:0010628 9.92 TNF MIR29A INS IGF1 AMH
3 cellular protein metabolic process GO:0044267 9.81 PRL INS IGFBP1 IGF1
4 positive regulation of cell migration GO:0030335 9.8 MIR29A INS IGF1R IGF1 CGA
5 insulin receptor signaling pathway GO:0008286 9.71 INS IGFBP1 IGF1R
6 phosphatidylinositol-mediated signaling GO:0048015 9.67 ZP3 IGF1R IGF1
7 positive regulation of protein kinase B signaling GO:0051897 9.65 TNF MIR29A MIR199A1 INS IGF1R
8 regulation of osteoclast differentiation GO:0045670 9.58 TNF FSHR
9 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.57 MIR199A1 IGF1
10 insulin-like growth factor receptor signaling pathway GO:0048009 9.56 IGF1R IGF1
11 transcytosis GO:0045056 9.55 IGF1R FSHR
12 female gonad development GO:0008585 9.54 FSHR FOXL2 CYP19A1
13 uterus development GO:0060065 9.5 FSHR FOXL2 CYP19A1
14 positive regulation of cell proliferation GO:0008284 9.5 PRL MIR141 INS IGF1R IGF1 GDF9
15 positive regulation of protein complex disassembly GO:0043243 9.46 TNF IGF1R
16 oocyte growth GO:0001555 9.43 GDF9 FOXL2
17 gonad development GO:0008406 9.33 FSHR CGA AMH
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.02 TNF INS IGF1R IGF1 FSHR

Molecular functions related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.56 MIR483 MIR29A MIR199A1 MIR141
2 insulin-like growth factor I binding GO:0031994 9.16 IGFBP1 IGF1R
3 insulin receptor binding GO:0005158 9.13 INS IGF1R IGF1
4 hormone activity GO:0005179 9.1 PRL INS IGF1 GNRH1 CGA AMH

Sources for Ovarian Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....